Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis

Trial Profile

Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Lopixibat chloride (Primary)
  • Indications Intrahepatic cholestasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INDIGO
  • Sponsors Lumena Pharmaceuticals; Shire
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
    • 02 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2018.
    • 22 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top